

# Judith Feucht, MD

\*21.08.1984, female

## Contact information:

Address: Cluster of Excellence "iFIT" (EXC2180) and University Children's Hospital  
University Hospital Tübingen, Hoppe-Seyler-Str. 1, 72076 Tübingen  
Phone: +49 7071 2983706  
Email: judith.feucht@med.uni-tuebingen.de

**Current position:** iFIT Junior Research Group leader and physician scientist

## University training and advanced academic qualifications

2011 – 2015 Residency, University Children's Hospital, University Hospital Tübingen, Germany  
2011 Dissertation, Medical doctor (M.D.), University Children's Hospital, University of Tübingen, Germany. Supervisors: Prof. Dr. Rupert Handgretinger and Prof. Dr. Tobias Feuchtinger  
2005 – 2011 Medical school, University of Tübingen, Germany  
Clinical electives abroad: Bludenz (Austria), St. Pierre (Réunion, France), Gabun (Africa), Sydney (Australia), Baden (Switzerland)

## Postgraduate professional career

Since 09/2020 Resident Physician and Junior Research Group Leader, Cluster of Excellence (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies (iFIT)", University of Tübingen and University Children's Hospital Tübingen, Germany  
2015 – 2020 Postdoctoral Research Fellow, Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA.  
Mentor: Michel Sadelain, M.D., Ph.D.  
2011 – 2015 Resident Physician, Department of General Pediatrics, Hematology and Oncology, University Children's Hospital Tübingen, Germany.  
Mentors: Prof. Dr. Rupert Handgretinger and Prof. Dr. Tobias Feuchtinger

## Honors and awards (selected)

2020 Awarded the ERC Starting Grant „ERC-2020-STG“  
2019 Awarded the Kind-Philipp Prize 2018 for research achievements in Pediatric Oncology/Hematology  
2018 CIMT Travel Award from the Association for Cancer Immunotherapy  
2017 Awarded the Erna Brunner Prize for research achievements in Pediatric Oncology/Hematology, Germany  
2016 – 2018 Fellowship of the German Research Foundation (DFG), Germany  
2015 – 2016 Fellowship of the Care-for-Rare Foundation, Germany  
2013 – 2014 Fellowship of the German Center for Infection Research (DZIF), Germany

## Reviewing activities

2020 - today Ad hoc reviewer for Nature and Nature Medicine

## Selected Memberships

GPOH Gesellschaft für Pädiatrische Onkologie und Hämatologie

## Patents

WO/2019/133969: Enhanced Chimeric Antigen Receptors and uses thereof  
WO/2020/172177: Combinations of multiple Chimeric Antigen Receptors for Immunotherapy  
PCT/US2020/016290: Senolytic CAR T cells targeting a cell surface and secreted senescence (provisional, filed 01/2020)

**Selected oral meeting presentations**

12/2020	ASH Annual Meeting, virtual (invited oral presentation)
11/2019	AIO Symposium, Academic Drug Development in Oncology, Berlin, Germany (invited oral presentation)
08/2019	Immuno-Oncology-Summit 2019, Boston, USA (invited oral presentation)
03/2019	Clinical Application of CAR T cells, New York, USA (oral presentation)
12/2018	ASH Annual Meeting, San Diego, USA (poster presentation)
04/2016	EBMT Annual Meeting, Valencia, Spain (poster presentation)
03/2015	EBMT Annual Meeting, Istanbul, Turkey (oral presentation)

**Publications**

\*authors contributed equally to the work/ IF: Impact Factor

**First author publications**

1. Amor C\*, Feucht J\*, Leibold J\*, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, Kulick A, Houlihan S, Peerschke E, Friedman SL, Ponomarev V, Piersigilli A, Sadelain M, Lowe SW. *Senolytic CAR T cells reverse senescence-associated pathologies*. Nature, 583(7814):127-132, 2020. **IF: 42.778**
2. Feucht J, Sadelain M. *Function and evolution of the prototypic CD28 $\zeta$  and 4-1BB $\zeta$  chimeric antigen receptors*. IOTECH, 2590-0188, Vol: 8, Page: 2-11, 2020. IF pending.
3. Feucht J, Abou-El-Enein M. *Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies*. Mol Ther, 2020 Oct 7;28(10):2108-2110, 2020. **IF: 8.986**
4. Feucht J\*, Sun J\*, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. *Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency*. Nat Med, 25:82-88, 2019. **IF: 36.13**
5. Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T. *T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts*. Oncotarget, 22;7(47):76902-76919, 2016. **IF: 3.71**
6. Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, Greil J, Einsele H, Schlegel PG, Schuster FR, Kremens B, Rossig C, Gruhn B, Handgretinger R, Feuchtinger T. *Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT*. Blood, 125(12):1986-94, 2015. **IF: 17.54**
7. Feucht J\*, Leibold J\*, Halder A, Kayser S, Hartl L, Rammensee HG, Handgretinger R, Feuchtinger T. *Differential expression of THELPER 1 cytokines upon antigen stimulation predicts ex vivo proliferative potential and cytokine production of virus-specific T cells following re-stimulation*. Transpl Infect Dis, 16:713-23, 2014. **IF: 2.112**
8. Feucht J, Joachim L, Lang P, Feuchtinger T. *Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation*. Klin Padiatr. 2013, 225(3):164-9, 2013. **IF: 0.800**
9. Leibold J\*, Feucht J\*, Halder A, Stevanovic S, Kayser S, Handgretinger R, Feuchtinger T. *Induction of Thelper1-driven antiviral T-cell lines for adoptive immunotherapy is determined by differential expression of IFN- $\gamma$  and T-cell activation markers*. J Immunother, 35:661-9, 2012. **IF: 3.455**

**Other original publications**

10. Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T. *Protective T-cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections*. Mol Ther. 2021 May 28:S1525-0016(21)00303-8. **IF: 8.986**
11. Leibold J\*, Ruscetti M\*, Cao Z\*, Ho YJ, Baslan T, Zou M, Abida W, Feucht J, Han T, Barriga FM, Tsanov KM, Zamechek L, Kulick A, Amor C, Tian S, Rybczyk K, Salgado NR, Sánchez-Rivera FJ, Watson PA, de Stanchina E, Wilkinson JE, Dow LE, Abate-Shen C, Sawyers CL, Lowe SW. *Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis*. Cancer Discov, 10(7):1038-1057, 2020. **IF: 29.497**

12. Blaeschke F, Paul MC, Schuhmann MU, Rabsteyn A, Schroeder C, Casadei N, Matthes J, Mohr C, Lotfi R, Wagner B, Kaeuferle T, Feucht J, Willier S, Handgretinger R, Stevanović S, Lang P, Feuchtinger T. *Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy*. *Cytotherapy*, 21(9):973-986, 2019. **IF: 4.297**
13. Willier S, Cabanillas Stanchi KM, von Have M, Binder V, Blaeschke F, Feucht J, Feuchtinger T, Döring M. *Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study*. *BMC Cancer*, 19(1):1118, 2019. **IF: 3.030**
14. Cabanillas Stanchi KM, Ebinger M, Hartmann U, Queudeville M, Feucht J, Ost M, Koch MS, Malaval C, Mezger M, Schober S, Weber S, Michaelis S, Lange V, Lang P, Handgretinger R, Döring M. *Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies*. *Drug Des Devel Ther*, 13:3439-3451, 2019. **IF: 3.216**
15. Cabanillas Stanchi KM, Queudeville M, Malaval C, Feucht J, Schlegel P, Dobratz M, Seitz C, Müller I, Lang P, Handgretinger R, Döring M. *Comparison of procalcitonin and C-reactive protein as early diagnostic marker for the identification of transplant-related adverse events after allogeneic hematopoietic stem cell transplantation in pediatric patients*. *J Cancer Res Clin Oncol*, 10.1007/s00432-019-03008-9, 2019. **IF: 3.332**
16. Ruscetti M\*, Leibold J\*, Bott MJ\*, Fennell M, Kulick A, Chen CC, Baslan T, Salgado NR, Feucht J, Sanchez-Rivera FJ, Tian S, Romesser PB, Poirier JT, Rudin CM, Stanchina E, Manchado E, Sherr CJ, and Lowe SW. *NK cell-mediated cytotoxicity contributes to the efficacy of a cytostatic drug combination in lung cancer*. *Science*, 362:1416-1422, 2018. **IF: 41.845**
17. Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring M, Feucht J, Feuchtinger T. *Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia*. *Cancer Immunol Immunother*, 67(7):1053-1066, 2018. **IF: 4.900**
18. Köstlin N, Vogelmann M, Spring B, Schwarz J, Feucht J, Härtel C, Orlikowsky TW, Poets CF, Gille C. *Granulocytic myeloid-derived suppressor cells from human cord blood modulate T-helper cell response towards an anti-inflammatory phenotype*. *Immunology*, 152(1):89-101, 2017. **IF: 4.147**
19. Döring M, Cabanillas Stanchi KM, Queudeville M, Feucht J, Blaeschke F, Schlegel P, Feuchtinger T, Lang P, Müller I, Handgretinger R, Heinz WJ. *Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation*. *J Cancer Res Clin Oncol*. 143(7):1281-1292, 2017. **IF: 3.332**
20. Döring M, Cabanillas Stanchi KM, Klinker H, Eikemeier M, Feucht J, Blaeschke F, Schwarze CP, Ebinger M, Feuchtinger T, Handgretinger R, Heinz WJ. *Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia*. *Med Mycol*. 55(4):375-384, 2017. **IF: 2.851**
21. Boekstegers AM, Blaeschke F, Schmid I, Wiebking V, Immler S, Hoffmann F, Bochmann K, Müller S, Grünewald TGP, Feucht J, Feuchtinger T. *MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD*. *Bone Marrow Transplant*, 52(8):1221-1224, 2017. **IF: 4.674**
22. Heinz WJ, Cabanillas Stanchi KM, Klinker H, Blume O, Feucht J, Hartmann U, Feuchtinger T, Lang P, Handgretinger R, Döring M. *Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation*. *Med Mycol*. 54(2):128-37, 2016. **IF: 2.851**
23. Döring M, Cabanillas Stanchi KM, Feucht J, Queudeville M, Teltschik HM, Lang P, Feuchtinger T, Handgretinger R, Müller I. *Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients*. *Ann Hematol*, 95(2):311-23, 2015. **IF: 2.850**
24. Döring M, Cabanillas Stanchi KM, Mezger M, Erbacher A, Feucht J, Pfeiffer M, Lang P, Handgretinger R, Müller I. *Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation*. *BMC Cancer*, 15:607, 2015. **IF: 2.933**
25. Kayser S, Boß C, Feucht J, Witte KE, Scheu A, Bülow HJ, Joachim S, Stevanović S, Schumm M, Rittig SM, Lang P, Röcken M, Handgretinger R, Feuchtinger T. *Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy*. *Oncoimmunology*, 4(5):e1002723, 2015. **IF: 5,503**

26. Schlegel P, Lang P, Zugmaier G, Ebinger M, Kreyenberg H, Witte KE, Feucht J, Pfeiffer M, Teltschik HM, Kyzirakos C, Feuchtinger T, Handgretinger R. *Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab*. *Haematologica*. 99(7):1212-9, 2014. **IF: 7.570**

**Funding and participated grants (selected)**

- 2015-2016 CAR T cell therapy against high risk neuroblastoma, Care-for-Rare Foundation, Germany; role: PI
- 2016-2018 Developing combined treatment approaches with GD2-specific CAR T cells and ICB against high-risk neuroblastoma; German Research Foundation, Germany; role: PI
- 2018-2020 Next generation CAR therapy with a novel CD28-based CD19 CAR, Technology Development Fund, New York, USA; role: grant contribution
- 2020-2022 Development of antibody-based senolytic approaches, Technology Development Fund, New York, USA; role: grant contribution
- 2020-2025 R01 (1R01AG065396-01), Toward development of senolytic CAR T cells, New York, USA; role: grant contribution
- 2021-2026 CARsen: Senolytic CAR T cells as novel therapeutic concept for solid tumors and senescence-associated diseases, ERC; role: PI

Tübingen, June 04, 2021

